news | MaaT Pharma

Posters

ASH readout a curtain raiser for Maat Pharma’s main act

mrossettiDecember 6, 2018

Media

Microbiome Therapy Shows Early Promise in Cancer Patients

mrossettiDecember 5, 2018

Posters

The Odyssee study: Results of a prospective multicenter trial – ASH 2018

mrossettiDecember 2, 2018

Press Releases

MaaT Pharma Presents Positive Phase 1b/2a Study Results in Acute Myeloid Leukemia Patients at the ASH 2018 Annual Meeting

mrossettiDecember 2, 2018

Media

le Magazine de la Santé : Lutter contre les complications des traitements contre la Leucémie grâce à nos médicaments Microbiote !

Découvrez comment MaaT Pharma restaure les fonctions du Microbiote Intestinal de patients traités par Chimiothérapie et…

mrossettiNovember 29, 2018

Media

Feedback from BIO Europe 2018 (Copenhagen) – What’s new in the Microbiome Industry ? – Labiotech.eu

mrossettiNovember 28, 2018

Press Releases

MaaT Pharma to Present Positive Results from Phase 1b/2a Clinical Trial at 60th American Society of Hematology (ASH) Annual Meeting

MaaT PharmaNovember 6, 2018

Press Releases

MaaT Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of Lead Product MaaT013, a First-in-Class Biotherapeutic to Treat Acute GvHD

Microbiome restoration biological drug product to be tested for safety and overall survival impact in…

MaaT PharmaOctober 12, 2018

Posters

Posters – EMBL

MaaT PharmaSeptember 18, 2018

Press Releases

MaaT Pharma Presents Product Analysis of Its First-in-Class High Diversity Microbiome Therapeutic

Results from in silico analysis using MaaT Pharma’s data analysis platform, GutPrint, demonstrate therapeutic rationale…

MaaT PharmaSeptember 18, 2018

NextPrevious »

ASH readout a curtain raiser for Maat Pharma’s main act

Microbiome Therapy Shows Early Promise in Cancer Patients

The Odyssee study: Results of a prospective multicenter trial – ASH 2018

MaaT Pharma Presents Positive Phase 1b/2a Study Results in Acute Myeloid Leukemia Patients at the ASH 2018 Annual Meeting

le Magazine de la Santé : Lutter contre les complications des traitements contre la Leucémie grâce à nos médicaments Microbiote !

Feedback from BIO Europe 2018 (Copenhagen) – What’s new in the Microbiome Industry ? – Labiotech.eu

MaaT Pharma to Present Positive Results from Phase 1b/2a Clinical Trial at 60th American Society of Hematology (ASH) Annual Meeting

MaaT Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of Lead Product MaaT013, a First-in-Class Biotherapeutic to Treat Acute GvHD

Posters – EMBL

MaaT Pharma Presents Product Analysis of Its First-in-Class High Diversity Microbiome Therapeutic

Categories

MAAT PHARMA

COMPANY

RESSOURCES

CONTACT